Compositions and methods for the treatment of “plaques and tangles” in humans and animals

1. A method for preventing, reducing or treating amyloid plaques and/or neurofibrillary tangles in a mammalian subject comprising administering an effective amount of a composition comprising an Uncaria tomentosa extract and an oolong tea extract.

2. The method of claim 1 , wherein the amount of Uncaria tomentosa extract and an oolong tea extract administered is between about 100-500 mg of Uncaria tomentosa extract and about 100-500 mg oolong tea extract.

3. The method of claim 1 , wherein the mammalian subject has amyloidosis.

4. The method of claim 3 wherein the amyloidosis is associated with age-associated memory loss, age-associated memory impairment (AAMI), mild cognitive impairment (MCI), Alzheimer's disease, Down's syndrome, dementia pugilistica, cognitive dysfunction syndrome, canine cognitive dysfunction, multiple system atrophy, inclusion body myositosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, Nieman-Pick disease type C, cerebral β-amyloid angiopathy, dementia associated with cortical basal degeneration, the amyloidosis of type 2 diabetes, the amyloidosis of chronic inflammation, the amyloidosis of malignancy and Familial Mediterranean Fever, the amyloidosis of multiple myeloma and B-cell dyscrasias, the amyloidosis of prion diseases, Creutzfeldt-Jakob disease, Gerstmann-Straussler syndrome, kuru, scrapie, the amyloidosis associated with carpal tunnel syndrome, senile cardiac amyloidosis, familial amyloidotic polyneuropathy, and the amyloidosis associated with endocrine tumors.

5. The method of claim 1 , wherein administration of the composition inhibits formation, deposition, accumulation, or persistence of amyloid fibrils or amyloid plaques.

6. The method of claim 1 , wherein the extracts are formulated for administration by one of the routes selected from pills, tablets, caplets, soft or hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixirs, suspensions, emulsions, solutions, cold and hot beverage preparations, syrups, tea bags, aerosols, suppositories, sterile injectable solutions, or sterile packaged powders.

7. The method of claim 1 , wherein administration of the composition inhibits formation, deposition, accumulation, or persistence of beta-amyloid containing plaques.

8. The method of claim 1 , wherein the mammalian subject has a tauopathy.

9. The method of claim 8 wherein the tauopathy is selected from Alzheimer's disease, frontotemporal lobar degeneration with tat inclusions (FLTD-tau), Pick's disease, progressive supranuclear palsy, corticobasal degeneration, agryophlic grain disease, prion disease, amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam (also called Lytico Bodig disease), Parkinson's disease, tangle-predominant dementia, ganglioma, ganglioglioma, gangliocytoma, meningiomatosis, subacute sclerosing panencephalitis, lead encephalopathy, tuberous sclerosis, Hallervorden-Spatz disease, lipofuscinosis, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), dementia pugilistic, concussion, single or repeated blows to the head, and post-traumatic stress disorder.

10. The method of claim 1 , wherein administration of the composition inhibits formation, deposition, accumulation, or persistence of tau protein containing tangles.

11. The method of claim 1 , wherein administration of the composition improves cognitive performance and/or slows cognitive decline in the mammalian subject.

12. The method of claim 11 , wherein the amount of Uncaria tomentosa extract and an oolong tea extract administered is between about 100-500 mg of Uncaria tomentosa extract and about 100-500 mg oolong tea extract.

13. The method of claim 1 , wherein administration of the composition improves learning, memory, cognition, focus and/or concentration in the mammalian subject, wherein the mammalian subject has age-associated memory loss, age-associated memory impairment (AAMI), mild cognitive impairment (MCI) or Alzheimer's disease.

14. The method of claim 13 wherein the amount of the combination of Uncaria tomentosa extract and oolong tea extract administered is between about 100-500 mg of Uncaria tomentosa extract and about 100-500 mg oolong tea extract.

15. The method of claim 1 , wherein the mammalian subject has experienced single- or multiple concussions, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), post-traumatic stress disorder, brain aging, age-associated memory loss, age-associated memory impairment (AAMI), mild-cognitive impairment (MCI) or Alzheimer's disease.

16. The method of claim 15 , wherein the amount of the combination of Uncaria tomentosa extract and the oolong tea extract administered is between about 100-500 mg of Uncaria tomentosa extract and about 100-500 mg oolong tea extract.

17. The method of claim 1 , wherein the mammalian subject is an aged dog or aged cat.